Chengdu Ruimu Biomedical Technology

Chengdu Ruimu Biomedical Technology is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of innovative ophthalmic therapies. The company focuses on addressing unmet medical needs in blinding eye diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Their core expertise lies in a proprietary sustained-release drug delivery platform that aims to reduce the frequency of intraocular injections, improving patient compliance and long-term outcomes. Ruimu's lead candidate, RM-001, is a small molecule multi-target tyrosine kinase inhibitor designed for long-acting treatment of retinal vascular diseases. The company has attracted significant investment from leading venture capital firms to advance its clinical pipeline. Ruimu Biomedical aims to become a leader in the field of long-acting ophthalmic medications within the Chinese market and beyond.